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ABSTRACT 
The present study was conducted to determine the effect of consuming canola oil vs. other common 
oil(s) on the lipid profile and anthropometric parameters of dyslipidemic adults. Eighty urban affluent 
dyslipidemic adults (40 experimental, 40 control) of age 30–45 years were enrolled from hospital based 
preventive health check programs for a 16-week non-randomized intervention trial. Dietary and lifestyle 
modification advice for management of lipid levels was provided to both the groups. Canola oil was 
provided for routine consumption only to the experimental group whilst the control group was advised 
to consume their usual oil(s) in recommended amounts (15 ml/day). Height, weight, Body Mass Index 
(BMI), Waist Circumference (WC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), 
Total Cholesterol (TC) and Triglycerides (TG) were measured at the beginning of the study (0 weeks), 
post run-in period (4 weeks) and post intervention period (12 weeks). Self-reported checklist was used to 
measure monthly compliance. Mixed effect linear regression and quantile linear mixed models were used 
to analyze the change in the parameters over time. There was no significant difference in the compliance 
towards dietary and lifestyle advice between both the groups (p=0.525; 0.795). The difference of changes 
in the lipid profile and anthropometric measurements between the groups observed over time was not 
statistically significant (Weight: p=0.206, BMI: p=0.553, WC=0.40, TC: p=0.505, TG: p=0.167, LDL: 
p=0.271, HDL: p=0.504). Hence, there was no difference in the effects of consuming canola oil vs. other 
common oil(s) in managing dyslipidemia. Similar beneficial changes were observed with consumption 
of both canola as well as other common oil(s).
 
Keywords: canola, cholesterol, dyslipidemia, management, oil(s)
*Corresponding Author: tel: +91-9810271147, email: bani.aeri@ihe.du.ac.in
J. Gizi Pangan, Volume 15, Number 3, November 2020                                                                           159 
Available online: http://journal.ipb.ac.id/index.php/jgizipangan                J. Gizi Pangan, November 2020, 15(3):159-168
Accredited based on DGHE, Republic of Indonesia No. 28/E/KPT/2019                            DOI: 10.25182/jgp.2020.15.159-168
ISSN 1978-1059  EISSN 2407-0920            
INTRODUCTION
Cardiovascular diseases (CVDs) have 
a major share in global Non-Communicable 
Diseases (NCD) related mortality (WHO 2018). 
Indians in particular are at a greater risk owing 
to their genetic predisposition (Sai et al. 2012). 
CVDs occur a decade earlier among Indians 
(Mean age: 53±11.4 years) as compared to their 
European, American, Middle Eastern, even 
African counterparts (Mean age: 58.8±12.2 
yrs), mainly because of lower prevalence of 
protective factors such as moderate to high 
intensity exercise, consumption of fruits and 
vegetables (Joshi 2007; Xavier 2008). Other 
leading risk factors such as high systolic blood 
pressure (≥140 mmHg), fasting plasma glucose 
(≥126 mg/dl) levels and total cholesterol (≥200 
mg/dl) have also been identified for CVD 
deaths in India, which have only increased 
in line with the CVD deaths (Prabhakaran et 
al. 2018). In fact, these risk factors increase 
exponentially with age once Indians reach 
the 30-39 years age group (Gupta et al. 2009).
As CVDs and their related risk factors 
continue to rise, India in particular will suffer 
the economic impact of this trend, if preventive 
measures are not taken (Chauhan & Aeri 2015). 
Hence, the most effective combative strategy in 
this regard would be to focus on alleviating these 
risk factors. The present study focussed on one 
such risk factor, i.e. dyslipidemia, defined as the 
occurrence of total cholesterol, TC levels ≥200 
mg/dl; Triglycerides, TG levels ≥150 mg/dl, 
Low density lipoprotein, LDL levels ≥130 mg/
dl and high-density lipoprotein, HDL ≤40 mg/dl 
alone or in combination (Chandra et al. 2014).
In 2008, the global prevalence of 
raised cholesterol (≥190 mg/dl) among 25+ 
year old adults were 38.9% (females-40.2%, 
males-37.3%) and that of India were 27.9% 
(females-29.5% and males-26.3%) (WHO 
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2008). More recent prevalence data can be found 
in Indian studies. In 2014, the age adjusted 
prevalence were: TC ≥200 mg/dl- 25.1% and 
24.9%, LDL-c ≥130 mg/dl- 16.3% and 15.1%, 
HDL-c <40 mg/dl-men and <50 mg/dl-women- 
33.6% and 52.8%, total: HDL-c ≥4.5- 29.4% and 
16.8% and TG ≥150 mg/dl- 42.1% and 32.9% 
males and females respectively (Guptha et al. 
2014). In the ICMR INDIAB study, prevalence of 
high TC levels was 13.9%, high TG- 29.5%, low 
HDL-c-72.3% and high LDL-c-11.8%. At least 
one abnormal lipid parameter was seen among 
79% of men and women (Joshi et al. 2014). More 
recently, prevalence of elevated TC was reported 
in 25.4% and 35.6%, LDL-c in 28.1% and 35.1%, 
TG in 33.9% and 26.8%, low HDL-c in 54.9% 
and 64.4% and total: HDL-c in 45.1% and 36.4% 
men and women respectively (Gupta et al. 2016). 
Hence, the prevalence varies across studies but is 
definitely very high when translated into numbers.
Both Indian (Chandra et al. 2014) as 
well as international guidelines for treatment 
of dyslipidemia recommend modifications in 
terms of diet, physical activity, smoking, alcohol 
consumption etc. (NHLBI 2005; Catapano et al. 
2016). Within these guidelines, the quality and 
quantity of dietary fats to be consumed have 
been focused upon. Even the WHO/FAO expert 
consultation report advises <10% of total calorie 
intake from saturated fatty acids (SFAs), about 
6–10% from polyunsaturated fatty Acids (PUFAs; 
1–2% n3 and 5–8% n6) and rest of the fat derived 
energy intake from monounsaturated fatty acids 
(MUFAs) (Report of the Joint WHO/FAO 2003). 
Given the criteria, many edible oils have been 
promoted on the basis of their fatty acid profiles 
as cholesterol lowering agents, including canola 
oil. Canola oil is low in SFAs, high in MUFAs and 
PUFAs specifically n-3 PUFAs as compared to 
many commonly consumed oils such as soybean, 
rice bran, safflower, sunflower etc. (ICMR 2010). 
Several research studies have documented the 
beneficial effects of consuming canola oil in diet. 
A meta-analysis conducted to study the effect 
of various fatty acids concluded that substitution 
of canola oil into the diet starting at only 2% 
can produce an overall Coronary Artery Disease 
(CAD) risk reduction of  21% (Mozaffarian & 
Clarke 2009). In a  study, replacing dairy fat with 
rapeseed oil (canola oil) led to  reduced levels of 
serum cholesterol (-17%), TG (-20%) and LDL-c 
(-17%), TC:HDL-c (-21%), apolipoprotein (apo) 
B/apo A‐I ratio (-4%) from baseline and also 
modestly increased serum lipoprotein(a) (+6%) 
(Iggmann et al. 2011). Similar benefits have also 
been reported among obese males. After daily 
supplementation of 50 g of canola oil vs. olive 
oil  over 4 weeks, there was an increase in serum 
n-3 fatty acids (from 3.59±0.26% to 4.17±0.21%) 
and a reduction in TC  (by 0.55±0.14 mmol/l), 
LDL levels (by 0.45±0.11 mmol/l) along with 
certain pro-inflammatory markers as compared 
to olive oil (Kruse et al. 2015). Most recently, 
two systematic review and meta-analysis studies 
have also reiterated the beneficial effects of 
consuming canola oil. One of them concluded that 
consuming canola oil for >30 days can reduce TC 
and LDL levels among >50-year-old individuals 
specifically in comparison with sunflower oil and 
saturated fat (Ghobadi et al. 2019). The other 
specifies improvement in several cardiometabolic 
markers compared with saturated fat, sunflower 
and olive oil with greatest benefits occurring 
when  15% of the total energy intake was 
consumed from canola oil (Amiri et al. 2020). 
 At the same time, beneficial effects of 
many other oils have also been documented. In 
a review comparing olive oil, sunflower oil, fish 
oils and palm oil for their cardiovascular effects, 
it was concluded that all these oils have beneficial 
effects on cardiovascular health if supplemented 
in appropriate proportions. Considering only 
those that are used for cooking, both olive and 
sunflower oil were found to be effective in 
lowering serum cholesterol while palm oil was 
found to have a neutral to mild effect. Further, 
olive oil reduced oxidative stress and both 
sunflower and palm oil were found to have 
some anti-arrhythmogenic benefits. Sunflower 
oil was found to be less desirable due to its pro-
oxidant effect when used for frying (Bester et 
al. 2010). However, in another study, palmolein 
oil consumption increased plasma and total 
LDL-c levels compared with olive oil while 
intake of olive oil demonstrated reduced LDL 
concentration and slight tendencies in reduction 
of total:HDL ratio but no change in HDL levels 
were seen in either (Tholstrup et al. 2011). 
Similar effect of olive oil consumption has been 
documented elsewhere (Oliveras-López et al. 
2013). Its capability of increasing the HDL levels, 
its size, promoting its stability and enhancing the 
HDL oxidative status have also been documented 
(Hernáez 2017). Consumption of rice bran 
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oil (30 ml/day) can improve LDL levels as 
well as the antioxidant status significantly in 
hyperlipidemic individuals (Bumrungpert et al. 
2019). Hence, many other commonly consumed 
oils can also favorably change lipid levels.
With this background, the present study 
was conducted to determine any effects of 
consuming canola oil vs. other commonly 
consumed oil(s) in managing dyslipidemia in 
terms of any change in lipid profile (LDL, HDL, 
TC and TG) and anthropometric measurements 
(Weight, BMI, WC). 
METHODS
Design, location, and time
Non-randomized intervention trial of 16 
weeks: 4 weeks of run-in period and 12 weeks 
of intervention period. Participants were enrolled 
for the study from selected preventive health 
check-up centres in Delhi-National Capital 
Region, India during 2012–2015.
Sampling
Sample size was computed to be 40 (each 
for experimental and control group) considering 
a drop-out rate of 20% (level of significance 5% 
and power 80%). The sample size was calculated 
on the basis of the mean and standard deviation 
values from a cross over study conducted on adult 
participants (Kuriyan et al. 2005). The formula 
used was (Rosner 1995):
(σ12 + σ22) + (z1-α/2 + z1-β)2 
              Δ2 
where, Δ = μ2 – μ1, (μ1, σ1) and (μ2, σ2) are 
means and variances of the two respective groups, 
z1-α/2 = 1.96, z1-β = 0.84
A total of 112 participants gave a written 
informed consent to participate in this study. They 
were requested to come for a follow up visit after 
a month’s run-in period. Only 88 participants 
came for the follow up visit. At this point, their 
lipid profile and anthropometric data were re-
collected (post run-in). These participants were 
then divided into experimental and control group 
using the alternation technique. All participants 
whose identification/serial number was odd were 
assigned to the experimental group (n=45) while 
those with even numbers were assigned to the 
control group (n=43). During the intervention 
period, there were 8 more drop-outs; 5 from 
experimental group and 3 from control group 
due to a frequent travelling schedule that did 
not allow adherence to the intervention for long 
periods of time. 
The inclusion criteria for the study subjects 
were; age: 30–45 years; TC ≥200 mg/dl and/or 
TG ≥150 mg/dl and/or LDL ≥130 mg/dl and/
or HDL ≤40 mg/dl; willingness to participate 
and  written informed consent. Those with liver 
disease, kidney disease, diabetes, heart disease 
or malignancy, pregnant and lactating mothers 
as well as those on lipid lowering drugs were 
excluded.
Intervention
Diet and lifestyle advice for lipid lowering 
based on the NCEP-ATP III (2002) guidelines was 
provided to both groups through a personalized 
diet plan. Counselling for maintaining optimum 
physical activity, stress management, smoking 
cessation and restricting alcohol intake was also 
given. Experimental group was provided canola 
oil in vacuum packaged bottles bought directly 
from the seller by the investigators for daily 
cooking of any kind while the control group 
consumed their usual edible oil(s) which were 
mustard, olive, sunflower, soybean, rice bran oil, 
clarified butter or ghee and coconut oil. They did 
not consume canola oil as ascertained through a 
survey with the sample population and continued 
using the oil(s) they were using at the beginning 
of the study throughout the study period. Advised 
dosage was 15ml/day for both the groups.
The study protocol was approved by 
the scientific committee of Max Healthcare, 
Institutional Ethics Committee, Institute of 
Home Economics and the Max Healthcare Ethics 
Committee. The study was also registered with 
the Indian Council of Medical Research (ICMR) 
clinical trial registry (REF/2013/04/004857).
Data collection
Standard techniques were used to collect 
anthropometric data i.e. height, weight (Seth & 
Singh 2005) and waist circumference; WC (WHO 
2011) and data on lipid profile i.e. TC using 
CHOD-PAP method (Roeschlau et al. 1974); 
TG  using GPO Trinder method (McGowan et 
al. 1983); LDL calculated using the Friedwald’s 
equation (Tietz et al. 2006) and HDL levels 
ascertained using the phosphotungsticacid 
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method (Rifai & Warnick 1994) were collected 
three time periods: at 0 weeks, the beginning 
of the study (pre-intervention stage), after 4 
weeks of run-in period (post run-in stage) and 
then again after 12 weeks of intervention with 
canola oil/commonly consumed oil(s) (post-
intervention stage). Height and weight data were 
used to calculate Body Mass Index, BMI of the 
participants (WHO 2019). 
Compliance to the intervention was 
assessed using a monthly self-report checklist 
wherein the participants marked the number of 
days they deviated from the dietary and lifestyle 
advice as well as canola oil consumption (for 
experimental group only). The compliance of 
the participants (during run-in period of 4 weeks, 
intervention period of 12 weeks and overall study 
period of 16 weeks) was calculated in terms of 
mean number of days the advice was adhered 
to. Percentage compliance was computed by 
dividing the mean no. of complaint days with 
the total no. days.  Compliance was considered 
to be good if the participants consumed canola 
oil/other oil(s) for at least 30 days during the 
substitution period. This criterion was derived on 
the basis of similar intervention studies that have 
documented an effect of such interventions in as 
less as 4 weeks (Kruse et al. 2015; Ghobadi et al. 
2019; Bumrungpert et al. 2019).
Data analysis
Independent t-test was used to assess 
difference between the groups on the basis of 
compliance. The outcome variables were tested 
for normality and were found non-normal. Hence, 
log transformations were applied. All variables 
except WC and BMI followed normality post 
transformation hence, their mean values were 
reported. Thus, independent t-test and Mann 
Whitney U test were used to determine any 
difference in the LDL, HDL, TC, TG levels and 
BMI and WC values at the beginning of the study 
respectively. Both the study groups were also 
tested for age and gender matching using a chi 
square test.
To study the effect of the intervention 
among both the study groups, the main outcome 
variables of the study were statistically analyzed 
for change over time. Mixed effect linear 
regression models were used to test the difference 
in the change of mean values of LDL, HDL, 
TC and TG over time between experimental 
and control group as these variables followed 
normality after log transformation. However, 
BMI and WC values did not follow the normality 
assumption even after the transformation hence, 
Quantile Linear Mixed Models (QLMM) were 
used to assess the difference in change of median 
values of BMI and WC over time between the two 
study groups. These models were used to analyze 
the difference of values between two groups and 
the within participants variations of values over 
the three time periods.  In both types of analysis, 
three models were applied: (1) Model 1: The 
change was measured over time by study groups 
only; (2) Model 2: Age and gender were adjusted 
in the model while assessing the change over 
time; (3) Model 3: Effect of days of compliance 
for diet and exercise were also included along 
with age and gender in the models.
Different statistical analysis software 
was used for this analysis. Linear mixed effect 
model and multinomial logistic regression model 
analysis were carried out using SPSS 17.0 while 
the Quantile Linear Mixed Model (QLMM) 
analysis was carried out using software R 3.1.3
RESULTS AND DISCUSSION
The experimental and control group were 
age and gender matched (p=0.382 and 1.00). 
There was no significant difference between the 
two groups in weight, median BMI, median WC, 
mean TC, TG, LDL and HDL levels at the pre-
intervention stage (p=0.510; 0.697; 0.913; 0.713; 
0.223; 0.363; 0.929 respectively). Thus, both the 
study groups were essentially similar at the pre-
intervention stage. 
Table 1 shows the mean numbers of days 
for compliance of both the groups towards 
dietary and lifestyle advice. With an overall 
compliance of approximately 70–75%, no 
significant difference was observed between the 
groups (dietary advice: p=0.525, lifestyle advice: 
p=0.795). In addition, the compliance of the 
experimental group for canola oil consumption 
was 105±14.18 days i.e. 87.5%. The results have 
been reported with reference to the parameters at 
the beginning of the study.
Change in anthropometric parameters 
At the end of the first month i.e. the run-
in period, there was significant decline in the 
weight and BMI of experimental group as well 
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as the control group (p-experimental<0.001; 
p-control<0.001 and p-experimental<0.001, 
p-control=0.001 respectively) (Table 2, Table 
3). WC decreased in the control group but not 
significantly (p=0.278) while no change was 
observed in the experimental group. However, at 
the end of the intervention period, a significant 
decline in the weight, BMI and WC was observed 
in both the groups. Further, on comparing the 
extent of decline between the two groups, no 
significant difference was observed (Table 2, 
Table 3).
Change in lipid levels
By the end of the run-in period, both the 
groups exhibited a significant decline in the TC 
levels (p-experimental=0.035; p-control=0.003). 
Even the LDL levels declined significantly but 
with a marginal significance in the experimental 
group (p-experimental=0.055; p-control=0.003). 
On the other hand, both the TG as well as 
the HDL levels did not change significantly 
(p-experimental=0.669; p-control=0.830 and 
(p-experimental=0.181; p-control=0.753 
respectively). In the next four months i.e. by 
Table 1. Comparison of study groups on the basis of the mean number of days of compliance
Compliance Total number of days
Experimental Control
p
Mean±SD % Mean±SD %
Dietary advice
Run-in period 30 20±7.62 66.66 20.08±8.79 66.93 0.802
Intervention period 120 91.83±18.35 76.53 89.80±26.02 74.83 0.661
Total study period 150 111.83±23.26 74.55 109.88±31.98 73.25 0.525
Lifestyle advice
Run-in period 30 18.95±7.68 63.17 19.20±8.52 64 0.754
Intervention period 120 92.90±17.41 77.42 87.23±29.13 72.69 0.761
Total study period 150 111.85±22.65 74.57 106.43±34.78 70.95 0.795
Canola oil
























Weight (kg) 74.66±12.34 73.94±12.07 72.66±11.28 -2.68 72.89±11.05 71.86±10.71 70.2±9.84 -3.69











WC (cms) 91 (86–95.88) 91 (86–94) 87.5 (84–91) -3.85 91 (86–94) 87.5 (86–94) 86 (81–93.25) -5.49
LDL (mg/dl) 155.01±26.81 149.54±23.8 138.22±19.54 -10.83 161.75±33.22 153.51±32.77 139.82±28.29 -13.56
HDL (mg/dl) 38.87±8.62 38.28±7.83 38.43±6.7 -1.31 39.5±11 39.5±10.81 38.86±10.08 -1.62
TC (mg/dl) 232.48±25.59 226.53±24.12 211.53±20.57 -9.01 236.6±37.35 229.49±38.71 212.23±34.71 -10.3
TG (mg/dl) 195.43±57.98 194.25±46.86 171.95±44.78 -12.01 183.33±62.51 181.1±55.87 169.48±57.94 -7.55
BMI: Body Mass Index; WC: Waist Circumference; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TC: Total Cholesterol; TG: Triglycerides
Table 2. Overall change in the anthropometric parameters and lipid profile levels 
164                                                                        J. Gizi Pangan, Volume 15, Number 3, November 2020
Chauhan & Aeri
the end of the intervention period, there was 
a significant decline in all the lipid levels 
except HDL (TC: p-experimental<0.001; 
p-control<0.001; TG: p-experimental<0.001; 
p-control=0.029; LDL: p-experimental<0.001; 
p-control<0.0001; HDL: p-experimental=0.016; 
p-control=0.831). Further, the extent of decline 
in TC, TG and LDL levels was not found be 
significantly different between the two groups 
(Table 2, Table 4).
Hence, the study participants were age 
and gender matched, similar in terms of their 
anthropometric parameters and lipid levels at the 
beginning of the study and also had similar extent 
of compliance to the intervention. The only 
difference between the groups was the type of oil 
they consumed. By the end of the study period, 
it was observed that the weight, BMI, WC, TC, 
TG and LDL levels of both the groups decreased 
significantly. 
Further, it is worth noting that while the 
mean HDL levels did not change desirably in 
both the groups i.e., they did not increase, the 
levels also did not decrease by the end of the 
study period. Since HDL is known to be cardio-
protective, a decline in its levels is not desirable 
(Nagao et al. 2018).
Key observation of the study is that the 
difference of these changes between the two study 
groups was not statistically significant (p>0.05) 
i.e. the changes observed were similar in both the 
groups whether they consumed canola oil or their 
usual oils in routine. 
As discussed in the introduction section, 
several studies have documented the beneficial 
effects of canola oil consumption over other oil(s) 
in terms of reduction in lipid profile level and 
even other cardiovascular risk markers such as 
Apo b: Apo A-I ratio (Iggmann et al. 2011; Kruse 
et al. 2015; Ghobadi et al. 2019; Amiri 2020). 
Table 3. Change in the anthropometric parameters of the participants
Experimental (n=40) Control (n=40)
Study period Estimate↑ Standard error pɸ Estimate↑ Standard error pɸ
Weight1
Pre-intervention Reference Reference Reference Reference
Post run-in -0.009 0.002 <0.001** -0.014 0.004 <0.001**
Post intervention -0.026 0.005 <0.001** -0.036 0.007 <0.001**
Difference change 
between the groups p
#= 0.206
Body mass index2
Pre-intervention Reference Reference Reference Reference
Post run-in -0.285 0.061 <0.001** -0.361 0.105 0.001**
Post intervention -0.738 0.136 <0.001** -0.923 0.172 <0.001**
Difference of change 
between the groups p
#=0.553
Waist circumference2
Pre-intervention Reference Reference Reference Reference Refer-ence
Post run-in -0.462 0.237 0.057* -0.751 0.228 0.001**
Post intervention -2.34 0.487 <0.001** -2.92 0.577 <0.001**
Difference of change 
between the groups p
#=0.40
*Significant (p<0.05); ** Highly significant (p<001); ↑Estimates are beta coefficients indicating the change in parameters unit time; pΦ: Shows 
the significance of change in the parameters; p#: Shows the significance of difference of change between the groups; 1Mean log transformed 
values; 2 Median values
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However, our study did not confirm this finding. 
Instead, we found that effect of consuming 
canola oil was not superior to consuming usual 
oil(s) like mustard, olive, sunflower, soybean, 
rice bran oil, clarified butter or ghee and coconut 
oil as seen in our control group participants. 
These results are in line with an intervention 
with hypoenergetic diet enriched in rapeseed 
oil vs. an olive oil diet among individuals with 
metabolic syndrome. The investigators observed 
a significant reduction in body weight of both 
the rapeseed oil and olive oil group (-7.8 v. -6.0 
kg). There were significant decreases in the TC 
(-0.30 mmol/l and -0.38 mmol/l) and LDL-c 
(-0.22 mmol/l and -0.28 mmol/l) levels also 
with no inter-group differences.  Here, too the 
HDL levels did not change in both the study 
groups.  However, rapeseed oil group did show 
a distinction of improved TG levels (-0.045 
mmol/l) that did not occur in the olive oil group 
(Baxheinrich et al. 2012). Our results also concur 
with a recent randomized control trial that 
reported no difference between two groups that 
consumed canola oil or, in this case a specific oil 
i.e. sunflower oil for 6 weeks. Both the groups 
showed significant decline in LDL (Canola 
Experimental (n=40) Control (n=40)
Study period Estimate↑ Standard error pɸ Estimate↑ Standard error pɸ
Total cholesterol
Pre-intervention Reference Reference Reference Reference
Post run-in -0.026 0.012 0.035* -0.031 0.018 0.003**
Post intervention -0.093 0.015 <0.001** -0.109 0.026 <0.001**
Difference of change 
between the groups p
#= 0.505
Triglycerides
Pre-intervention Reference Reference Reference Reference
Post run-in -0.007 0.016 0.669 -0.005 0.025 0.830
Post intervention -0.119 0.022 <0.001** -0.070 0.031 0.029*
Difference of change 
between the groups p
#= 0.167
Low density lipoprotein
Pre-intervention Reference Reference Reference Reference Refer-ence
Post run-in -0.034 0.017 0.055* -0.055 0.018 0.003**
Post intervention -0.109 0.021 <0.001** -0.147 0.026 <0.001**
Difference of change
between the groups p
#=0.271
High density lipoprotein
Pre-intervention Reference Reference Reference Reference Refer-ence
Post run-in -0.012 0.009 0.181 -0.002 0.007 0.753
Post intervention -0.003 0.016 0.834 -0.003 0.015 0.831
Difference of change between 
the groups p
#=0.504
*Significant (p<0.05); ** Highly significant (p<0.01); ↑Estimates are beta coefficients indicating the change in mean value of log transformed lipids 
per unit time;  pΦ: Shows the significance of change in mean of log transformed values; p#: Shows the significance of difference between the groups
Table 4. Change in the lipid profile of the participants
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group: 129.54±39.74 mg/dl to 116.12±35.83 mg/
dl and Sunflower group: 140.55±41.29 mg/dl  to 
122.95±32.97), TC (Canola group: 220.13±41.94 
mg/dl to 194.31±39.45 mg/dl and sunflower 
group: 223.95±43.81 mg/dl to 196.45±35.28 
mg/dl) and TG levels (197.14±103.23 mg/dl 
to 172.49±78.25 mg/dl and sunflower group: 
189.02±110.02 mg/dl to 171.04±88.69 mg/dl) 
with the only exception being an elevation in the 
HDL levels (Canola group: 44.24±12.31 mg/dl to 
47.28±11.90 and sunflower group: 44.82±12.29 
mg/dl to  46.73±11.35 mg/dl) but no significant 
change in the anthropometric parameters of the 
participants as compared to our study probably 
because the study did not involve giving dietary 
and lifestyle advise to the participants (Saedi et 
al. 2017). This was another key observation of 
our study since obesity (increased weight, BMI 
and WC) is a known risk factor for CVDs.
CONCLUSION
There are several studies that have 
documented evidence of beneficial effects of 
canola oil consumption as against other edible 
oils. However, a few others have also shown no 
difference in the benefits conferred by consuming 
canola oil or other commonly consumed 
oil(s) as in the case of our study. We observed 
similar improvements in the lipid levels and 
anthropometric parameters in both the groups 
implying no additional benefits of consuming 
canola oil in specific. Thus, our results imply 
that similar improvements in lipid levels and 
anthropometric parameters can also be brought 
about by using commonly available oils with 
lower price points and this can help in managing 
dyslipidemia more economically. Future research 
studies can focus on the role of following 
dietary and lifestyle modifications as against 
consumption of specific oil(s) in managing 
dyslipidemia among adults. 
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